Dr. Carl Ola Landgren | CureTalks
Dr. Carl Ola Landgren is Professor of Medicine, chief of Myeloma Program and leader of Experimental Therapeutics Program at the University of Miami. He is a board-certified hematologist-oncologist affiliated with Memorial Sloan Kettering Cancer Center. His research focuses on the mechanisms underlying progression from precursor disease to frank malignancy; prognostic factors associated with progression; role of MRD (minimal residual disease) negativity and biological mechanisms associated with MRD status drug development; identification of novel targets and intervention of residual/refractory disease. His area of expertise include Myeloma, Monoclonal Gammopathy, MGUS, and Smoldering Myeloma. Dr. Landgren received his medical degree from Karolinska Institute Faculty of Medicine and has been practicing for more than 20 years.
Related Talks
Goals and challenges of developing a patient focused myeloma center of excellence
The multiple myeloma treatment field has undergone several changes over the past 10-20 years. The average overall survival has changed from 1-3 years…
Multiple Myeloma: Minimal Residual Disease Testing as an End Point Treatment
Most multiple myeloma patients, even those in complete response, may show signs of relapse at some point of time. So, testing and quantifying…
MSKCC Expert Dr. Ola Landgren on Can High Risk Disease Progress Cure Myeloma ?
Is high risk disease progress, the key to a cure for all myeloma patients? And what can researchers do to get new therapies…